Long-term changes in Sjögren’s disease: a 9-year prospective follow-up study from the SJOGRENSER Registry
- 01.07.2025
- Observational Research
- Verfasst von
- Mónica Fernández-Castro
- Zulema Plaza-Almuedo
- Jose Rosas
- Victor Martínez-Taboada
- Alejandro Olivé
- Raúl Menor-Almagro
- Belen Serrano-Benavente
- Judit Font-Urgelles
- Angel García-Aparicio
- Sara Manrique-Arija
- Jesus Alberto García-Vadillo
- Ruth López-González
- Javier Narváez
- Beatriz Rodriguez-Lozano
- Carlos Galisteo
- Jorge González-Martín
- Paloma Vela-Casasempere
- Cristina Bohórquez
- Celia Erausquin
- Beatriz Paredes-Romero
- Leyre Riancho-Zarrabeitia
- Sheila Melchor-Diaz
- Jose Maria Pego-Reigosa
- Sergi Heredia
- Clara Moriano
- Maria Angeles Blazquez-Cañamero
- Paula Estrada
- Enrique Júdez
- Joaquín María Belzunegui
- Consuelo Ramos
- Fernando Sánchez-Alonso
- Jose Luis Andreu
- the Systemic Autoimmune Diseases Group of the Spanish Society of Rheumatology (EAS-SER)
- Erschienen in
- Rheumatology International | Ausgabe 7/2025
Abstract
The objective of SjögrenSER Prospective (SjD-PROS) was to evaluate the improvement, stability or progression of SjD in clinical practice. SjD-PROS is an observational, longitudinal, multicenter study of SjD in Spain. Participants from the prior transversal phase were invited to a follow-up visit after 9.5 years. Data were collected via interviews and medical records. Variables were analyzed using means, medians and frequencies. Statistical associations were assessed using T student test, Kruskal–Wallis and the Chi-square test. We included 314 patients, 95% women (mean age of 66 years; mean disease duration of 17 years). At follow-up visit, the most frequent systemic manifestations were arthralgias (54%) and hematological involvement (49%), with arthralgias being significantly less frequent than at baseline visit (p < 0.001); the most affected organs were the lung (15.6%) and the kidney (11.5%). Half of the patients in SjD-PROS, had positive rheumatoid factor, 16% less than at baseline visit; β2-microglobulin was significantly elevated compared to baseline visit (62.5%, p < 0.001). Articular, pulmonary, hematological and biological domains of ESSDAI index showed the greatest changes, both in improvement and worsening, and the greatest activity. Systemic treatments use was significantly higher in patients showing activity in ESSDAI. This study offers valuable insights into the most variable clinical and serological manifestations throughout the course of SjD. ESSDAI domains showing the greatest changes reflected the greatest treatments needs. These findings allow for patient stratification based on phenotype, a crucial step in designing follow-up protocols.
Anzeige
- Titel
- Long-term changes in Sjögren’s disease: a 9-year prospective follow-up study from the SJOGRENSER Registry
- Verfasst von
-
Mónica Fernández-Castro
Zulema Plaza-Almuedo
Jose Rosas
Victor Martínez-Taboada
Alejandro Olivé
Raúl Menor-Almagro
Belen Serrano-Benavente
Judit Font-Urgelles
Angel García-Aparicio
Sara Manrique-Arija
Jesus Alberto García-Vadillo
Ruth López-González
Javier Narváez
Beatriz Rodriguez-Lozano
Carlos Galisteo
Jorge González-Martín
Paloma Vela-Casasempere
Cristina Bohórquez
Celia Erausquin
Beatriz Paredes-Romero
Leyre Riancho-Zarrabeitia
Sheila Melchor-Diaz
Jose Maria Pego-Reigosa
Sergi Heredia
Clara Moriano
Maria Angeles Blazquez-Cañamero
Paula Estrada
Enrique Júdez
Joaquín María Belzunegui
Consuelo Ramos
Fernando Sánchez-Alonso
Jose Luis Andreu
the Systemic Autoimmune Diseases Group of the Spanish Society of Rheumatology (EAS-SER)
- Publikationsdatum
- 01.07.2025
- Verlag
- Springer Berlin Heidelberg
- Erschienen in
-
Rheumatology International / Ausgabe 7/2025
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X - DOI
- https://doi.org/10.1007/s00296-025-05909-0
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.